Related Experiment Video
Updated: Jun 7, 2025

Author Spotlight: Quantitative Detection of DNA Protein Crosslinks and Their Post-Translational Modifications
Published on: April 21, 2023
DAPK enhances DDX20 protein stability via suppression of TRIM25-mediated ubiquitination-based DDX20 degradation
Yan Ye1,2,3, Xiuli Zhang1,2, Chenyi Wang4
1College of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, Fujian, China.
Abstract:
We have previously found that the DAPK-DDX20 signaling axis exerts an anti-cancer activity in hepatocellular carcinoma (HCC) by inhibiting the GTPase activity of CDC42, thereby reducing the invasive and migratory capabilities of cancer cells without affecting cell proliferation. DDX20 serves as an intermediate protein regulated by DAPK in the control of CDC42. Specifically, DAPK enhances DDX20 protein levels by suppressing DDX20 degradation. However, the mechanism underlying DAPK regulation of DDX20 remains unclear. In the current study, we discovered that DDX20 is degraded through the ubiquitin-proteasome pathway and identified TRIM25 as the E3 ubiquitin ligase of DDX20. TRIM25 mediates the proteasomal degradation of DDX20 by binding to, and ubiquitinating the 1-244 amino acid region of DDX20. Moreover, DAPK interacts with this 1-244 segment of DDX20, inhibiting its ubiquitination and enhancing its stability, despite the lack of direct physical interaction between DAPK and the 1-244 region of DDX20. Remarkably, DAPK, TRIM25, and DDX20 form a ternary protein complex in cells, and knockdown of TRIM25 leads to a reduction in the cellular levels of the binary DAPK-DDX20 complex, suggesting that TRIM25 acts as an important intermediate protein linking DAPK and DDX20. TRIM25 functions as an oncogene in liver cancer, as shRNA-mediated silencing of TRIM25 inhibits cell migration and invasion. Therefore, these novel findings of the interaction among these three proteins not only enhances our knowledge of the downstream molecular network of DAPK and its possible role in the development of HCC, but also provides potential druggable targets for the future development of novel anticancer drug therapeutics.
Insights
Death-associated protein kinase (DAPK) stabilizes DDX20 by inhibiting TRIM25-mediated degradation, suppressing hepatocellular carcinoma (HCC) cell invasion. This reveals a new DAPK-TRIM25-DDX20 axis for HCC drug development.
Area of Science:
- Molecular oncology
- Cell signaling pathways
Background:
- The DAPK-DDX20 axis shows anti-cancer activity in hepatocellular carcinoma (HCC) by inhibiting CDC42 GTPase activity, reducing cancer cell invasion and migration.
- DAPK enhances DDX20 protein levels by suppressing its degradation, but the precise mechanism remains unclear.
Purpose of the Study:
- To elucidate the mechanism by which DAPK regulates DDX20 stability.
- To identify the E3 ubiquitin ligase responsible for DDX20 degradation.
- To investigate the role of TRIM25 in the DAPK-DDX20 signaling pathway and its implications in HCC.
Main Methods:
- Investigated DDX20 degradation via the ubiquitin-proteasome pathway.
- Identified TRIM25 as the E3 ubiquitin ligase for DDX20 using binding and ubiquitination assays.
- Analyzed the formation of a ternary complex involving DAPK, TRIM25, and DDX20.
- Utilized shRNA to assess the functional impact of TRIM25 knockdown on cell migration and invasion.
Main Results:
- DDX20 is degraded through the ubiquitin-proteasome pathway, with TRIM25 identified as the specific E3 ubiquitin ligase.
- TRIM25 ubiquitinates DDX20 in the 1-244 amino acid region, promoting its proteasomal degradation.
- DAPK interacts with the 1-244 region of DDX20, inhibiting ubiquitination and enhancing DDX20 stability.
- DAPK, TRIM25, and DDX20 form a ternary complex; TRIM25 knockdown disrupts the DAPK-DDX20 complex.
- TRIM25 functions as an oncogene in liver cancer, as its silencing inhibits cell migration and invasion.
Conclusions:
- TRIM25 mediates the proteasomal degradation of DDX20, and DAPK stabilizes DDX20 by inhibiting this process.
- The DAPK-TRIM25-DDX20 interaction reveals a novel regulatory mechanism in HCC.
- TRIM25 acts as an oncogene in liver cancer, and targeting the DAPK-TRIM25-DDX20 axis offers potential therapeutic strategies for HCC.
More Related Videos
08:232 in 1: One-step Affinity Purification for the Parallel Analysis of Protein-Protein and Protein-Metabolite Complexes
Published on: August 6, 2018
09:13Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
Published on: November 22, 2024
Related Concept Videos
Anaphase Promoting Complex
DNA Damage can Stall the Cell Cycle
Abnormal Proliferation
The Unfolded Protein Response
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity